The latest biotech news

News and Trends 20 Nov 2023

M&As: what’s up with the ADC buying spree?

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]

November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 17 Nov 2023

With $700 million Q3 rise, U.K. biotech spearheads European recovery

The U.K.’s biotechnology landscape has witnessed an impressive surge in funding, clocking a robust £563 million ($700 million) in venture capital and public financings in the third quarter of 2023, according to Biotech Finance. This achievement marks a staggering 48% increase from the previous quarter and sets a formidable pace that is already on track […]

November 17, 2023 - 4 minutesmins - By Jules Adam

News and Trends 3 Nov 2023

BioTechX 2023: the highlights

BioTechX 2023, one of Europe’s largest conventions, that blends diagnostics, precision medicine and digital transformation in the field of healthcare, took place in the biotech hub of Basel, Switzerland. The event, which was held from October 4 to 6, hosted expert panelists who shared their knowledge on the digital transformation in pharma, leveraging artificial intelligence, […]

November 3, 2023 - 16 minutesmins - By Dylan Kissane

News and Trends 22 Sep 2023

U.S. approval for psychedelic drug MDMA nears after success in clinic

The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes after Australia became the first country to allow doctors to prescribe the drug to those struggling with mental health disorders like PTSD and depression. Recognizing […]

September 22, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 18 Sep 2023

Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities

The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […]

September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter

News and Trends 31 Jul 2023

Biogen acquiring Reata Pharmaceuticals for $7.3B

Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […]

July 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2023

FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment

The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy. The breakthrough designation is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan. In June 2023, NS-089/NCNP-02 was granted Rare […]

July 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Jul 2023

Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […]

July 28, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2023

New CHAIN Biotech funding to aid CADD therapeutic platform

CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […]

July 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jul 2023

Recbio shingles vaccine clinical trial approved

Jiangsu Recbio Technology Co., Ltd. has received notice of acceptance from China’s National Medical Products Administration (NMPA) to start a clinical trial for its self-developed novel adjuvanted recombinant shingles vaccine, REC610. Within 60 days from the date of acceptance, the company may carry out clinical trials in accordance with the submitted plan if no negative […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jul 2023

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jul 2023

Medicxi announces $400M fund for life science companies

Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients. Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

M&As: what’s up with the ADC buying spree?

With $700 million Q3 rise, U.K. biotech spearheads European recovery

BioTechX 2023: the highlights

U.S. approval for psychedelic drug MDMA nears after success in clinic

Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities

Biogen acquiring Reata Pharmaceuticals for $7.3B

FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment

Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

New CHAIN Biotech funding to aid CADD therapeutic platform

Recbio shingles vaccine clinical trial approved

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Medicxi announces $400M fund for life science companies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!